Clinical Trials Sponsored by Shanghai Institute Of Biological Products

Total 497 results

Shanghai Institute Of Biological Products

Not yet recruiting

Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma
Shanghai Institute Of Biological Products

Completed

Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

Influenza

China
Shanghai Institute Of Biological Products

Completed

Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years

Influenza, Human

China
Shanghai Institute Of Biological Products

Completed

Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live

Vaccine | Immunotoxicity

China
Shanghai Institute Of Biological Products

Completed

Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants

Influenza

China
Shanghai Institute Of Biological Products

Completed

A Clinical Trial of A Quadrivalent Influenza Vaccine

Influenza

China
Shanghai Institute Of Biological Products

Completed

Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old

Varicella

China
Shanghai Institute Of Biological Products

Completed

A Study Comparing SIBP-04 and Bevacizumab in Healthy Male Subjects

Healthy Male

China
Shanghai Institute Of Biological Products

Unknown

A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine

H7N9 Influenza

China
Shanghai Institute Of Biological Products

Completed

A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 Years

Herpes Zoster

China
Shanghai Institute Of Biological Products

Completed

A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL

Diffuse Large B-Cell Lymphoma

China
Shanghai Institute Of Biological Products

Completed

A Clinical Trial of PEGIFNα1b in Chinese Healthy Adults

Herpes Zoster

China
Shanghai Institute Of Biological Products

Completed

The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine

Influenza

China
Shanghai Institute Of Biological Products
Fudan University

Completed

A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer

HER2-positive Early Breast Cancer

China
Shanghai Institute Of Biological Products
Fudan University

Completed

A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.

Tumor

China
Shanghai Institute Of Biological Products
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.

Advanced Solid Tumor
Jiangsu Province Centers for Disease Control and...
Shanghai Institute Of Biological Products; Chengdu Institute of Biological...

Completed

Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults

Influenza | Pneumococcal Infection

China
Shanghai Municipal Center for Disease Control and...
Shanghai Institute Of Biological Products

Unknown

Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine

Varicella

China
Shanghai Institute Of Biological Products
First Affiliated Hospital Bengbu Medical College

Completed

A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia

Asymptomatic Hyperuricemia

China
Shanghai Institute Of Biological Products
Chinese Academy of Medical Sciences Dermatology Hospital

Completed

A Study Exploring Efficacy of Peginterferon in Patients With Herpes Zoster

Herpes Zoster

China
Lanzhou Institute of Biological Products Co., Ltd

Recruiting

Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

Lymphoma, Non-Hodgkin | Lymphoma, T-Cell

China
Wuhan Institute of Biological Products Co., Ltd

Active, not recruiting

To Identify the Immunogenicity and Safety of QIV in Children Aged 3-8 Years (QIV)

Influenza

China
Wuhan Institute of Biological Products Co., Ltd

Not yet recruiting

Clinical Study of F61 Injection in Healthy Chinese Subjects

COVID-19
Lanzhou Institute of Biological Products Co., Ltd

Unknown

A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB)

Overactive Bladder
Shanghai Institute Of Biological Products
Henan Center for Disease Control and Prevention

Unknown

A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine

H7N9 Influenza

China
Wuhan Institute of Biological Products Co., Ltd

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of DXP604 in Patients With Mild to Moderate COVID-19

COVID-19
Lanzhou Institute of Biological Products Co., Ltd

Unknown

A Study to Evaluate Botulinum Toxin Type A for Injection（HengLi®）for Prophylactic Treatment of Chronic Migraine

Chronic Migraine
Lanzhou Institute of Biological Products Co., Ltd

Completed

A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity

Cerebrovascular Accident
Centers for Disease Control and Prevention, China
Shanghai Institute Of Biological Products

Completed

A Post-marketing Safety Study of Inactivated, Split-virion Influenza Vaccine in Subjects Aged 3 Years and Older

Influenza | Vaccination Adverse Event
Shanghai Institute Of Biological Products
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Completed

A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer

Non-squamous Non-small-cell Lung Cancer

China
Shenzhen Kangtai Biological Products Co., LTD
Guangdong Provincial Institute of Biological Products And Materia Medica

Unknown

Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Neonates

Liver Diseases | Digestive System Diseases | Hepatitis B | Hepatitis

China
Changchun Keygen Biological Products Co., Ltd.
Guangdong Provincial Institute of Biological Products And Materia Medica

Completed

Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine

Chickenpox

China
Changchun Keygen Biological Products Co., Ltd.
Guangdong Provincial Institute of Biological Products And Materia Medica

Completed

Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine

Japanese Encephalitis | Chickenpox

China
Changchun Keygen Biological Products Co., Ltd.
Guangdong Provincial Institute of Biological Products And Materia Medica

Completed

Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine

Varicella

China
Shanghai Institute Of Biological Products
Shaanxi Provincial Center for Disease Control and Prevention

Not yet recruiting

A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.

Influenza
National Vaccine and Serum Institute, China
Beijing Institute of Biological Products Co Ltd.; Lanzhou Institute of Biological...

Active, not recruiting

Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above

COVID-19 Pneumonia

China
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Lanzhou Institute of Biological... and other collaborators

Recruiting

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

Coronavirus Infections | COVID-19 Pneumonia

United Arab Emirates
China National Biotec Group Company Limited
The University of Hong Kong; Beijing Institute of Biological Products Co Ltd.; Wuhan Institute of Biological Products Co., Ltd

Active, not recruiting

Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above (COVID-19)

COVID-19

Hong Kong
Institute of Clinical Research and Clinical Trial...
Biological E. Limited

Completed

Evaluate Safety of ComBe Five (Liquid) in Healthy Vietnamese Children Aged From 8 - 10 Weeks as a 3-dose Series, Interval for Each Dose is 4 Weeks

Safety, Pentavalent Vaccine

Vietnam
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Beijing Institute of Biological... and other collaborators

Recruiting

Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial

Coronavirus Infections | COVID-19

United Arab Emirates
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Beijing Institute of Biological... and other collaborators

Recruiting

A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)

COVID-19

United Arab Emirates
National Vaccine and Serum Institute, China
Lanzhou Institute of Biological Products Co., Ltd

Not yet recruiting

Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha)

Norwalk Gastroenteritis | Norovirus Infections
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Sichuan Center for Disease... and other collaborators

Completed

Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4

Covid19 | Pneumonia, Pneumococcal | Influenza, Human

China
Shanghai Public Health Clinical Center
Beijing Ditan Hospital; National Institute for the Control of Pharmaceutical...

Unknown

Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients

Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Influenza | Orthomyxoviridae Infections

China
China National Biotec Group Company Limited
Xiangya Hospital of Central South University; Beijing Institute of Biological... and other collaborators

Recruiting

Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population

COVID-19 | Hemolysis

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Wuhan Institute of Biological... and other collaborators

Completed

A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above (COVID-19)

COVID-19

Jordan, Bahrain, Egypt, United Arab Emirates
PATH
Beijing Bio-Institute Biological Products Co., Ltd., formerly Beijing TiantanBio

Completed

Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine

Poliomyelitis

Kenya
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.

Active, not recruiting

A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated (COVID-19)

Covid19

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.

Completed

Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and Above (COVID-19)

COVID-19 | COVID-19 Pneumonia

United Arab Emirates
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.

Active, not recruiting

A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTaP)

Whooping Cough | Tetanus | Diphtheria

China

Clinical Trials Sponsored by Shanghai Institute Of Biological Products

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations